ReNeuron’s interim results for the six months to 30 September 2017 showcased a crucial juncture in the company’s history. With the first of two US placebo-controlled, late-stage studies in chronic stroke starting in 2018 and dosing ongoing in the US Phase I/II study in retinitis pigmentosa, ReNeuron’s stem cell therapies are aimed at helping the disabled walk and the blind see. ReNeuron reported a loss of £9.6m for the six months (vs £7.7m in H117). In 2018 ReNeu
21 Dec 2017
ReNeuron Group - Biblical aspirations
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ReNeuron Group - Biblical aspirations
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
21 Dec 2017 -
Author:
Andy Smith -
Pages:
5
ReNeuron’s interim results for the six months to 30 September 2017 showcased a crucial juncture in the company’s history. With the first of two US placebo-controlled, late-stage studies in chronic stroke starting in 2018 and dosing ongoing in the US Phase I/II study in retinitis pigmentosa, ReNeuron’s stem cell therapies are aimed at helping the disabled walk and the blind see. ReNeuron reported a loss of £9.6m for the six months (vs £7.7m in H117). In 2018 ReNeu